SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0001104659-23-028984
Filing Date
2023-03-06
Accepted
2023-03-06 16:00:26
Documents
1
Group Members
5AM OPPORTUNITIES I (GP), LLC5AM OPPORTUNITIES I, L.P.5AM PARTNERS VI, LLCANDREW J. SCHWABKUSH PARMAR

Document Format Files

Seq Description Document Type Size
1 SC 13D tm238571d1_sc13d.htm SC 13D 145719
  Complete submission text file 0001104659-23-028984.txt   147400
Mailing Address 6200 LOOKOUT ROAD BOULDER CO 80301
Business Address 6200 LOOKOUT ROAD BOULDER CO 80301 720-647-8519
Enliven Therapeutics, Inc. (Subject) CIK: 0001672619 (see all company filings)

IRS No.: 000000000 | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-91465 | Film No.: 23708837
SIC: 2834 Pharmaceutical Preparations

Mailing Address 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107
Business Address 501 2ND STREET, SUITE 350 SAN FRANCISCO CA 94107 (415) 993-8565
5AM Ventures VI, L.P. (Filed by) CIK: 0001753037 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D